Team

Management

Dr. Hahn-Jun Lee, M.Sc., Ph.D.

President/CEO

MANAGEMENT

Dr. Lee is a serial entrepreneur who founded Curyx Bio, Inc. to develop disease modifying drugs for neurodegenerative diseases, inborn errors of metabolism, and autoimmune diseases. He founded (1) Epygenix Therapeutics, Inc which develops precision medicines for rare and intractable pediatric genetic epilepsy, (2) Polaryx Therapeutics, Inc which develops patient-friendly medicines for lysosomal storage disorders, (3) Focus Therapeutics, L.L.C., a business catalyst in the biotech-pharma industry, and (4) Medeoryx, Ltd, a cell and gene therapy company converting fibroblast to endothelial, pancreatic, and neuronal cells using both proprietary antisense oligomers and Tissue Nano-Transfection (TNT), and applying these tools to ischemic diseases and to diabetic ulcers.

He has an extensive experience in R&D, deal making, business development, and consulting for several top-notch health care venture capital firms and global pharma and biotech companies, including Doman Associates, Shire Human Genetic Therapies, P&G Pharma, Melior Discovery, CDI, etc. He also has consulted for several Korean biotechs, venture capital firms, and research institutes.

Dr. Lee was an Assistant Professor of Biotechnology in the Department of Orthopedic Surgery, College of Physicians and Surgeons, Columbia University in the city of New York. He also worked as a Staff Scientist at the RIKEN Brain Science Institute in Japan.

He obtained B.S. in Life Science from Sogang University, Seoul, Korea. He completed his M.S. and Ph.D. in applied biotechnology in the Department of Applied Biotechnology at the University of Tokyo, Japan.

Scientific Advisory Board

Chair of Scientific Advisory Board

Dr. Kalipada Pahan, Ph.D.

Scientific Advisory Board

Dr. Pahan is a Professor of Neurological Sciences, Biochemistry, and Pharmacology and the Floyd A. Davis, M.D., Endowed Chair in Neurology at the Rush University Medical Center in Chicago. He is also a Veterans Affairs Scientist at the Jesse Brown VA Medical Center. Currently, he is engaged in translational biomedical research involving multiple sclerosis, Parkinson's disease, dementia, Alzheimer's disease, and Batten disease. He is the Editor-in-Chief of the Journal of Multiple Sclerosis, Senior Editor of the Journal of Neuroimmune Pharmacology, Editor of three other prestigious scientific journals, and a chartered member of the Clinical Neuroimmunology and Brain Tumors study section at the NIH. He has over 175 publications.

He received the outstanding teaching award in 2000, the “Chancellor’s Council Silver U Award” in 2004, and the "Reinhardt Research Scholar Award” in 2005 from the University of Nebraska Medical Center. Recently, he also received VA merit awards from the US Department of Veterans Affairs and the Zenith award from the Alzheimer’s Association.

Helping people reclaim the simplest things of life is a reward more than worth the
investment of our time.

Curyxbio Team

Board of Directors

Chair of BOD: Alex Yang, J.D., L.L.M.

Board of Director

Mr. Yang has over 20 years of experience in advising and executing fund formation, cross-border transactions, and diverse investment experiences in multiple industry sectors.
He currently serves as chairs of BOD at Epygenix Therapeutics and Polaryx Therapeutics, and investment and risk committee member roles for various regional and country-focused private equity funds. Mr. Yang is formerly a managing partner at Kim & Chang and was a partner at Ernst & Young Hong Kong office leading regional financial services practice, including banking and capital markets, asset management and insurance.

Mr. Yang formerly worked at Morgan Stanley Hong Kong Office in the capacity of its Asia Private Equity and In-house Counsel, focused on buy-outs and grow-capital investments, real estate, special situation and infrastructure transactions across Asia. He also worked at Coopers & Lybrand and Ernst & Young New York offices in their international tax and consulting divisions.

Mr. Yang was graduated from both New York University School of Law with both J.D. and L.L.M. degrees and Binghamton University with Economics degree. He is a registered foreign attorney with the Hong Kong Law Society.

Dr. Hahn-Jun Lee, M.Sc., Ph.D.

Board of Director

Dr. Lee is a serial entrepreneur who founded Curyx Bio, Inc. to develop disease-modifying drugs for neurodegenerative disorders, inborn errors of metabolism, and autoimmune disorders. He founded (1) Epygenix Therapeutics, Inc which develops precision medicines for rare and intractable pediatric genetic epilepsy, (2) Polaryx Therapeutics, Inc which develops patient-friendly medicines for lysosomal storage disorders, (3) Focus Therapeutics, L.L.C., a business catalyst in biotech-pharma industry, and (4) Medeoryx, Ltd, a cell and gene therapy company converting fibroblast to endothelial, pancreatic, and neuronal cells using proprietary antisense oligomers and Tissue Nano-Transfection (TNT), and applying them to ischemic diseases and diabetic ulcer.

He has extensive experience in R&D, deal making, business development, and consulting for several top-notch health care venture capital firms and global pharma and biotech companies, including Doman Associates, Shire Human Genetic Therapies, P&G Pharma, Melior Discovery, CDI, and etc. He also has consulted for several Korean biotechs, venture capital firms, and research institutes.

Dr. Lee was an Assistant Professor of Biotechnology in the Department of Orthopedic Surgery, College of Physicians and Surgeons, Columbia University in the city of New York. He has also worked as a Staff Scientist at the RIKEN Brain Science Institute in Japan.

Investors

Curyx Partners Investment, LTD